Pfiz­er racks up its third can­cer drug OK in 2 months, but is it enough to re­place reg­u­lar price hikes?

Pfiz­er has notched an­oth­er win for the late-stage drug pipeline, scor­ing an ac­cel­er­at­ed FDA ap­proval for lor­la­tinib, now head­ed for the mar­ket as Lor­bre­na. 

The drug is an ALK/ROS1 TKI for metasta­t­ic non-small cell lung can­cer — the lat­est in a line of these drugs — now ap­proved as a sec­ond-line treat­ment for pa­tients who have failed crizo­tinib and at least one oth­er ALK in­hibitor. And you can be sure that Pfiz­er didn’t pass on the chance of boast­ing about its third can­cer drug OK in the past 2 months, fol­low­ing ap­provals for its PARP ta­la­zoparib and da­comi­tinib.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER